患者和临床医生对严重失控喘生物治疗的偏好:一个离散选择实验 (DCE)
Melissa M Ross1, Yen Chung2, Tara Carr3
1Evidera Inc., Wilmington, NC, USA.
概括
患者和临床医生对喘生物治疗的偏好在很大程度上与有效性和安全性保持一致,但个体需求需要为个性化护理做出共享决策.
科学领域:
- 肺部病理学 肺部病理学
- 药物经济学 药物经济学
- 医疗保健服务研究 医疗服务研究
背景情况:
- 生物疗法在管理中度至重度喘方面取得了重大进展.
- 了解患者和临床医生的偏好对于优化治疗选择和坚持治疗至关重要.
- 现有的研究还没有完全阐明不同治疗属性的比较重要性,从两个角度来看.
研究的目的:
- 估计患者和临床医生对生物喘治疗特征的偏好.
- 为了比较患者和临床医生群体之间的这些偏好.
- 探索喘管理中声明偏好的根本原因.
主要方法:
- 在美国,对患有中度至重度喘的成年人和他们的治疗临床医生进行了一项横截面在线调查.
- 一个离散选择实验 (DCE) 评估了七个属性:疗效,风险和方便.
- 定性访谈探讨了调查答复背后的逻辑.
主要成果:
- 患者和临床医生都优先考虑减少恶化/住院和尽量减少注射部位反应.
- 与临床医生相比,患者对服用位置的价值更高.
- 偏好受事件频率,生活质量,合规性,财务影响和个人经验的影响.
结论:
- 喘治疗偏好主要是由疗效和最小化部位反应风险驱动的.
- 其他属性的偏好不同,凸显了共享决策的必要性.
- 个性化护理方法对于有效的喘管理至关重要.
相关概念视频
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
267
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
267
Antiasthma Drugs: β2-Adrenoceptor Agonists
245
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
245
Dose-Response Relationship: Selectivity and Specificity
6.6K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
6.6K
Inhaled Medications
249
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
249
Antiasthma Drugs: Leukotriene Modifiers
269
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
269


